MktsMarkets

Palisade Bio, Inc.
NASDAQ: PALIKey statistics
PALI News
Stories mentioning PALI from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | |||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | ||||||||
| Research & Development | 6,000 | 16,000 | ||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 10,748 | 9,981 | 2,922 | 2,843 | 2,310 | 3,382 | 3,593 | 4,211 |
| Operating Income (Loss) | (10,748) | (9,981) | (2,922) | (2,843) | (2,310) | (3,382) | (3,593) | (4,211) |
| Interest Income | ||||||||
| Interest Expense | 5.00 | 2.00 | 1.00 | 3.00 | 6.00 | 2.00 | ||
| Other Expense | 1,149 | 1,084 | 59.00 | 61.00 | 81.00 | 41.00 | 112.00 | 133.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (9,600) | (8,899) | (2,868) | (2,784) | (2,230) | (3,344) | (3,487) | (4,080) |
| Earnings Per Share (Basic) | (0.05) | (0.16) | (0.38) | (0.58) | (0.47) | (2.36) | (2.32) | (3.32) |
| Earnings Per Share (Diluted) | (0.05) | (0.16) | (0.38) | (0.58) | (0.47) | (2.36) | (2.32) | (3.32) |
| Weighted Average Shares Outstanding (Basic) | 209,664 | 55,670 | 7,474 | 4,797 | 4,796 | 1,416 | 1,500 | 1,228 |
| Weighted Average Shares Outstanding (Diluted) | 209,664 | 55,670 | 7,474 | 4,797 | 4,796 | 1,416 | 1,500 | 1,228 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About PALI
Palisade Bio, Inc. (NASDAQ: PALI) is a stock listed on the Nasdaq Stock Market under the ticker symbol PALI. It last traded at $0.9300 (Nov 19, 2026, 4:00 PM ET), down 1.8% on the day. That gives Palisade Bio a market capitalisation of $173.3M.
Over the past 52 weeks PALI has traded between $0.9400 and $2.85.
For the quarter ended Mar 31, 2026 it reported a net loss of $9.6M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$9.6M |
| Dec 31, 2025 | — | -$8.9M |
| Sep 30, 2025 | — | -$2.9M |
| Jun 30, 2025 | — | -$2.8M |
From Palisade Bio’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…